The average time taken for ALMUS PHARMACEUTICALS LIMITED to pay invoices to suppliers has been increasing steadily since the start of the data collection in September 2017. There was a significant increase in the average time taken in the last two periods, from 34 days in March 2019 to 46 days in March 2020.
The volatility of the company's payment behavior can be seen in the fluctuation of the percentage of invoices paid within 30 days. In September 2017, 85% of invoices were paid within 30 days, but this dropped to 55% in the last period (September 2020). There was also a significant increase in the percentage of invoices paid later than 60 days, from 0% in September 2017 to 24% in September 2020.
In the last three periods, there has been a decrease in the average time taken for ALMUS PHARMACEUTICALS LIMITED to pay invoices to suppliers. This is a positive trend showing that the company is making efforts to improve their payment behavior. However, there is still room for improvement as the average time taken is still above the standard payment period of 30 days. In terms of percentage, there has been an increase in the number of invoices paid within 30 days, from 50% in September 2020 to 85% in September 2021. This is a significant improvement, but there is still a high percentage of invoices (23%) being paid later than 60 days. The company's best period was in September 2019, where 94% of invoices were paid within 30 days. The worst period was in September 2020, where 24% of invoices were paid later than 60 days.
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Sept 2020 - 28 Feb 2021 | 29 Mar 2021 | 39 | 50% | 27% | 23% | 9% |
| 01 Mar 2020 - 31 Aug 2020 | 29 Sept 2020 | 46 | 40% | 32% | 28% | 12% |
| 01 Sept 2019 - 29 Feb 2020 | 27 Mar 2020 | 38 | 55% | 21% | 24% | 21% |
| 01 Mar 2019 - 31 Aug 2019 | 27 Sept 2019 | 34 | 62% | 35% | 4% | 12% |
| 01 Sept 2018 - 28 Feb 2019 | 29 Mar 2019 | 25 | 94% | 6% | 0% | 3% |
| 01 Mar 2018 - 31 Aug 2018 | 26 Sept 2018 | 33 | 69% | 28% | 3% | 28% |
| 01 Sept 2017 - 28 Feb 2018 | 29 Mar 2018 | 27 | 85% | 15% | 0% | 9% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Almus Pharmaceuticals Limited has standard payment terms ranging from 30 days of invoice receipt to 75 days of invoice receipt, with 50% of invoices paid within 30 days of receipt.
Were there any changes to the standard payment terms in the reporting period?
No
Any other information about payment terms
N/A
Maximum contractual payment period agreed
75
The main point of contact for disputes is the Almus Pharmaceuticals Ltd Financial Accountant, who manages the approval of invoices and follows internal processes to deal with and resolve disputes within 2 working days. Unresolved disputes are escalated at monthly reviews with Almus Pharmaceuticals Ltd senior management.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
ALMUS PHARMACEUTICALS LIMITED is a leading pharmaceutical company that focuses on providing sustainable healthcare solutions. They are committed to improving the well-being of individuals and communities through their high-quality products and services.
The company's sustainability program is at the core of their operations, with a strong focus on environmental, social, and economic aspects. They strive to reduce their carbon footprint, promote responsible sourcing of materials, and support local communities through various initiatives.
ALMUS PHARMACEUTICALS LIMITED offers a wide range of pharmaceutical products, including prescription medicines, over-the-counter drugs, and medical devices. They also provide healthcare services such as clinical trials and drug development. Their products are developed using the latest technologies and adhere to strict quality standards.
The company is led by a team of experienced professionals who are committed to achieving their goals of sustainability and providing innovative healthcare solutions. Some key people include the CEO, CFO, and Chief Medical Officer.
Customers can contact ALMUS PHARMACEUTICALS LIMITED through their website, which also provides information on their products, services, and sustainability initiatives. The registered office address is 20-22 Bedford Row, London, WC1R 4JS, United Kingdom.
In summary, ALMUS PHARMACEUTICALS LIMITED is a sustainable pharmaceutical company that offers high-quality products and services to improve the health and well-being of individuals and communities. Their commitment to sustainability, innovative products, and experienced leadership make them a leader in the healthcare industry.